Compare Citius Pharmaceuticals Inc (CTXR) vs Direxion Daily CSI China Internet Bull 2X Shares (CWEB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Direxion Daily CSI China Internet Bull 2X Shares — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while Direxion Daily CSI China Internet Bull 2X Shares trades at $18.25 (market cap $176.60M). The key difference: Direxion Daily CSI China Internet Bull 2X Shares is far larger — about 12.8× Citius Pharmaceuticals Inc's market cap, and Direxion Daily CSI China Internet Bull 2X Shares is more actively traded (440,349 versus 156,684). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Direxion Daily CSI China Internet Bull 2X Shares for 24 Days on average.
| CTXR | CWEB | |
|---|---|---|
Market Cap | $13.79M | $176.60M |
Volume | 156,684 | 440,349 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.82 | $55.62 |
52-Week Low | $0.48 | $17.39 |
Typical Hold Time | 16 Days | 24 Days |
Enterprise Value | $3.96M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
CWEB trades at $18.02, down 1.85% today amid bearish technical signals. The stock shows weak momentum with all 13 moving averages signaling sell, though oscillators are neutral. Recent news highlights China's AI ambitions and potential for China growth stocks to surge, providing thematic catalysts. Financial ratios remain undisclosed in current data.
Outlook hinges on China's tech sector recovery and AI growth narrative. Risks include geopolitical tensions and market volatility. The upcoming dividend of $0.07 in September 2026 offers income potential, but investors need clarity on fundamentals for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Direxion Daily CSI China Internet Bull 2X Shares
CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →
